2023 World Conference on Lung Cancer (Posters)-P2.14. Outcomes of Chemoimmunotherapy in Patients with ES-SCLC According to Liver Metastasis: A Multicenter Prospective Cohort Study

P2.14. Outcomes of Chemoimmunotherapy in Patients with ES-SCLC According to Liver Metastasis: A Multicenter Prospective Cohort Study - PDF(Abstract)

Back to course

Pdf Summary

Chemoimmunotherapy is the standard first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC). However, the association between liver metastasis and the efficacy of immunotherapy in ES-SCLC remains unclear. This study aimed to investigate the outcomes of chemoimmunotherapy in ES-SCLC patients with liver metastasis.<br /><br />A prospective cohort study was conducted in Japan, involving 207 patients with ES-SCLC who received carboplatin and etoposide with atezolizumab as first-line therapy. The patients were followed from September 2019 to September 2020. Progression-free survival (PFS) and overall survival (OS) were analyzed, and the differences between patients with and without liver metastasis were assessed.<br /><br />It was found that 31% of the patients had liver metastasis. The analysis revealed that patients with liver metastasis had significantly shorter PFS and OS compared to those without liver metastasis. The median PFS was 4.5 months for patients with liver metastasis, compared to 5.6 months for patients without liver metastasis. The median OS was 9.8 months for patients with liver metastasis, compared to 16.8 months for patients without liver metastasis. The 1-year PFS probability was also lower in patients with liver metastasis.<br /><br />Further analysis showed that liver metastasis was the only independent negative predictor for both PFS and OS. This suggests that liver metastasis is associated with significantly inferior survival outcomes after chemoimmunotherapy in ES-SCLC.<br /><br />In conclusion, this study found that liver metastasis is associated with poorer survival outcomes in ES-SCLC patients treated with chemoimmunotherapy. The findings highlight the need for further research to understand the resistance to immunotherapy in these patients.

Asset Subtitle

Yuhei Harutani

Meta Tag

Speaker Yuhei Harutani

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

chemoimmunotherapy

extensive stage small cell lung cancer

liver metastasis

efficacy of immunotherapy

prospective cohort study

carboplatin

etoposide

atezolizumab

progression-free survival

overall survival